World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
74
Citations
26843
World Ranking
19303
National Ranking
9618

Richard J. Gralla publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard J. Gralla sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 285 publications — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard J. Gralla D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard J. Gralla sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 74 D-Index — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Richard J. Gralla is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on the field of Medicine, with significant contributions in Oncology, Surgery, and Pulmonary and Respiratory Medicine. Additional areas of interest include Public Health, Environmental and Occupational Health, and Physiology.

The main topics addressed in their work comprise:

  • Nausea and vomiting management
  • Cancer survivorship and care
  • Anesthesia and Pain Management
  • Palliative Care and End-of-Life Issues
  • Lung Cancer Diagnosis and Treatment
  • Pathogenesis and Treatment of Hiccups
  • Lung Cancer Treatments and Mutations

Richard J. Gralla has published extensively in several academic journals. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Supportive Care in Cancer
  • Clinical Oncology
  • ESMO Open
  • Current Oncology

Notable recent papers authored or co-authored by Richard J. Gralla are:

  • Supportive Care: An Indispensable Component of Modern Oncology, 2020, Clinical Oncology
  • Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non-Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy, 2023, Journal of Clinical Oncology
  • 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting, 2024, ESMO Open
  • 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents, 2023, Supportive Care in Cancer
  • Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation, 2023, Supportive Care in Cancer

Richard J. Gralla has collaborated frequently with several researchers. Some of their frequent co-authors include:

  • Matti Aapro
  • Paul J. Hesketh
  • Hirotoshi Iihara
  • Karin Jordan
  • Florian Scotté

Best Publications

  • Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

    Frances A. Shepherd;Janet Dancey;Rodryg Ramlau;Karin Mattson

  • Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

    Joachim von Pawel;Joan H. Schiller;Frances A. Shepherd;Scott Z. Fields

  • The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

    Paul J. Hesketh;Steven M. Grunberg;Richard J. Gralla;David G. Warr

  • American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006

    Mark G. Kris;Paul J. Hesketh;Mark R. Somerfield;Petra Feyer

  • Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and Vomiting

    Richard J. Gralla;Loretta M. Itri;Sharon E. Pisko;Anna E. Squillante

  • Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines

    Richard J. Gralla;David Osoba;Mark G. Kris;Peter Kirkbride

  • Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

    F. Roila;J. Herrstedt;M. Aapro;R. J. Gralla

  • Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

    R. Gralla;M. Lichinitser;S. Van der Vegt;H. Sleeboom

  • Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

    Chee Khoon Lee;Chris Brown;Richard J. Gralla;Vera Hirsh

  • 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

    F. Roila;A. Molassiotis;J. Herrstedt;M. Aapro

  • Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.

    Chee Khoon Lee;Chee Khoon Lee;Johnathan Man;Sally Lord;Wendy Cooper;Wendy Cooper

  • Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

    David G. Warr;Paul J. Hesketh;Richard J. Gralla;Hyman B. Muss

  • Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients.

    Nael Martini;Mark G. Kris;Betty J. Flehinger;Richard J. Gralla

  • Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer—A quantitative western blot analysis

    Josep Dalmau;Henry M. Furneaux;Richard J. Gralla;Mark G. Kris

  • Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules.

    Richard J. Gralla;Ephraim S. Casper;David P. Kelsen;David W. Braun

  • Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin

    M G Kris;R J Gralla;R A Clark;L B Tyson

  • Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

    Rudolph M. Navari;Rick R. Reinhardt;Richard J. Gralla;Mark G. Kris

  • Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference

    Fausto Roila;Matti Aapro;Enzo Ballatori;Sussanne Borjeson

  • Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS)

    Patricia J. Hollen;Richard J. Gralla;Mark G. Kris;Lisa M. Potanovich

  • Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis

    Chee Khoon Lee;Chee Khoon Lee;Yi Long Wu;Pei Ni Ding;Pei Ni Ding;Sarah J. Lord;Sarah J. Lord

Frequent Co-Authors

Mark G. Kris
Mark G. Kris Memorial Sloan Kettering Cancer Center
David P. Kelsen
David P. Kelsen Memorial Sloan Kettering Cancer Center
David Osoba
David Osoba University of British Columbia
Nael Martini
Nael Martini Memorial Sloan Kettering Cancer Center
Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre
Christopher Cox
Christopher Cox Johns Hopkins University
Matti Aapro
Matti Aapro European CanCer Organisation
Gary R. Morrow
Gary R. Morrow University of Rochester Medical Center
Jacek Jassem
Jacek Jassem Gdańsk Medical University
Edith A. Perez
Edith A. Perez Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean committing to a traditional path. Prospective students with non-nursing backgrounds can consider direct entry msn programs for non-nursing majors, designed for those looking to transition to nursing at an accelerated pace. These programs allow you to earn a Master of Science in Nursing without prior nursing experience.

If you’re concerned about admissions requirements, you may want to review whats the easiest nursing program to get into?. Some schools offer more accessible entry points, making it easier for students from diverse backgrounds to start nursing careers.

Interested in healthcare support roles? Consider taking online medical coding classes with financial aid. Medical billing and coding is a fast-growing field that offers flexibility and strong job prospects, both on-campus and online.

For those seeking nursing options that minimize entrance exam stress, research nursing school that don't require teas. These programs eliminate the need for TEAS or HESI exam scores, streamlining your journey into healthcare.

Best Scientists Citing Richard J. Gralla

Trending Scientists

Recently Published Articles